Xpovio, also known by its generic name Selinexor, is a medication used to treat certain types of cancer, specifically multiple myeloma, a type of cancer that affects plasma cells in the bone marrow.
Xpovio is classified as a selective inhibitor of nuclear export (SINE) drug, which works by preventing certain proteins from leaving the nucleus of cancer cells, leading to their death.
Xpovio is typically prescribed for patients with multiple myeloma who have already received at least four previous treatments and whose cancer has become resistant to those treatments.
In combination with other medications, Xpovio has been shown to be effective in extending the overall survival and progression-free survival of patients with multiple myeloma. In some cases, Xpovio may also be used to treat other types of cancer, including lymphoma and solid tumors.
The recommended dosage of Xpovio is 80 mg, taken orally, once a week. It should be taken on the same day each week, with or without food, and swallowed whole with water.
The dosage may be adjusted by a healthcare provider based on the patient’s individual response and side effects. Xpovio should be taken as prescribed, and patients should not increase or decrease their dosage without consulting their healthcare provider.
If a dose is missed, it should be taken as soon as possible, unless it is within two days of the next scheduled dose.
Like all medications, Xpovio can cause side effects. Some common side effects include nausea, vomiting, diarrhea, fatigue, and decreased appetite. These side effects are generally mild to moderate in severity and can be managed with medication or other treatments.
Other potential side effects include low white blood cell counts, anemia, and thrombocytopenia. Xpovio may also increase the risk of infection and bleeding, so it is important for patients to avoid contact with others who are sick and to report any unusual bleeding or bruising to their healthcare provider.
In rare cases, Xpovio can cause more serious side effects, such as liver toxicity, kidney toxicity, and lung toxicity.
Patients should report any new or unusual symptoms to their healthcare provider immediately. Xpovio may also cause changes in electrolyte levels, which can lead to muscle weakness, confusion, and other symptoms. Patients should report any of these symptoms to their healthcare provider.
Xpovio is an effective medication for the treatment of multiple myeloma and other types of cancer. However, like all medications, it can cause side effects, and patients should discuss the benefits and risks of Xpovio with their healthcare provider before starting treatment.
Patients should also report any new or unusual symptoms to their healthcare provider immediately, and take Xpovio exactly as prescribed. With proper monitoring and management, Xpovio can be a valuable treatment option for patients with multiple myeloma and other types of cancer.